Michael Hölzel
@HolzelMichael
Followers
388
Following
79
Media
1
Statuses
75
Cancer Researcher, Tumor Microenvironment & Cancer Immunotherapy. Tweets are my own & no medical advice. Institute of Experimental Oncology. @IEO_HolzelLab
Bonn, Germany
Joined December 2019
Proud to be the mentor of @niklas_kluemper in UroAgeCare funded by @DFG_public. Now, the work on NECTIN4 amplifications predicting response to enfortumab vedotin in patients with mUC is published in @JCO_ASCO! Underscores the importance of #clinician #scientist #programmes.
Very happy to share our study published @JCO_ASCO ! https://t.co/gip2ikcX1G ➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4
0
1
10
Congrats to the 4 lead investigators Chun-Pu, Pierre, Astrid and Georgi from my lab @NKI_nl @oncodeinstitute + collaborators, reporting today in @Cancer_Cell several genes whose inactivation generates fitter immune T cells for enhanced tumor killing. https://t.co/QUqeBKW6zn
1
14
61
Exciting study reveals correlation between Trop2 target expression and anti-Trop2 ADC SG response in TNBC! @JCO_ASCO @ASCOPost @PTarantinoMD Membranous target gene expression crucial for ADC efficacy! ➡️ well-established for Her2, Nectin4, and Folr1 ! We need to consider the
2
8
24
NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 @ASCO #GU24! @Markuseckstein3 @OncoAlert @urotoday
4
53
132
Congrats to @egbawden & Thomas Gebhardt to this amazing work on #melanoma #immunity. Fantastic collaboration within @BonnMelbPhD. Thanks to @dfg_public @UniMelb @UniBonn
Excited to share our research that describes a variety of mechanisms that CD4+ T cells can employ to target melanoma!
2
4
15
Great to see EV+PEM being approved for 1L mUC based on EV-302 @tompowles1!🎉To further improve outcomes precision medicine is needed. Great overview of future directions by @MattGalsky🎯NECTIN4 again discussed to predict EV outcomes @OncoAlert @urotoday
https://t.co/6W0amrlmlE
link.springer.com
Current Treatment Options in Oncology - The treatment landscape for urothelial cancer has changed dramatically in the last 10 years, with the approval of several new treatments. At the same time,...
0
13
23
In three Phase III trials (mUC: IMvigor211, mRCC: IMmotion151, NSCLC: OAK) immunotherapy prolonged OS when baseline serum albumin was >35g/L -> Prediction of less immune fitness via simple albumin measurement? https://t.co/NVAyxJznOH
@OncoAlert @ClinTransImmuno @Doc_Bald @IEO_Bonn
onlinelibrary.wiley.com
We show in 3 different randomized trials, that serum albumin is a strong predictor of survival in patients with cancer treated with atezolizumab. The predictive value of serum albumin is independent...
0
10
19
Thanks @ViktorGruenwald for highlighting our work on the value of NECTIN4 status to predict EV response at a stellar symposium with @PGrivasMDPhD @drenriquegrande @OncoBellmunt at @myESMO
https://t.co/JmfOUNobel
@OncoAlert @urotoday @CCR_AACR Predictive biomarkers are needed !
aacrjournals.org
AbstractPurpose:. The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients...
1
17
27
It is so amazing. What a game changer
The @myESMO LBAs are out And a wow for PEMBRO/EV (Presidential) OS 31.5 vs 16.1 months (HR 0.45) PFS 12.5 vs 6.3 months (HR 0.47) P<0.00001 A historic change for 1L mUC since Von Der Maase JCO 2000 @tompowles1 #ESMO23 @OncoAlert
0
5
18
Verkaufsausstellung zugunsten von LebensWert: Mit einer Vernissage startet morgen im #CIO der #Uniklinik #Köln eine Ausstellung mit Werken des Kölner Künstlers Rudolf Watzlawik. Der Erlös kommt dem Verein LebensWert für krebskranke Patienten zugute. https://t.co/Z1Y76ZfcuG
0
3
7
Combo or sequence in #mRCC - odd question? #NIVOSWITCH tested switch-maintenance in mRCC 👉 ORR IO/TKI: 20 vs. 52% 👉 PFS IO/TKI: 3.0 vs. 11.9 mo 👉 2y-OS 64 vs. 66% 👉 supports use of IO-combos @tompowles1 @DrChoueiri @montypal @drenriquegrande
https://t.co/VndanrclHO
0
16
28
All true and indeed, we will not give up. We need #innovation for our (cancer) patients. @MSSOabcd is a nice example for a program supporting #cancer #research. Impressive young scientists & interdisciplinary spirit #CIOabcd. Thanks for funding @Krebshilfe_Bonn
1
0
8
Congratulations to @niklas_kluemper from @IEO_Bonn & Dept. of. Urology @UniklinikBonn for this prestigious research award @dgukongress. Happy to support & mentor. Perfect example for the success of #clinicianscientist programs @DGUrologie @UniBonn BONFOR @BMBF_Bund ACCENT
🔬 After years of relentless dedication two incredible minds have achieved a major scientific award @dgukongress ! Their journey in testis and urothelial cancer research is a testament to the power of collaboration and perseverance. @niklas_kluemper @tim_nestler @urotoday
1
0
18
Please read our latest article published in @BrJCancer on the characterization of #testiscancer related somatic-type malignancies on epigenetic and molecular level... @UniklinikDUS
@HHU_de
@MaGIC_GCT
@Uroweb
@DGUrologie
@uniGoettingen
https://t.co/sA5Yafo5bJ
nature.com
British Journal of Cancer - Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin,...
1
8
19
Excellent presentation by Gonzalo at the Single Domain Antibodies Meeting 2023 in Paris on his generic #CRISPR #CAR T cell platform! Important tool to improve #cellular #cancer #immunotherapies @UniBonn @ImmunoSens @MSSOabcd @IEO_GloddeLab
0
2
15
Great to see the work of my first PhD student finally published in @ScienceAdvances, extending our data-based modeling framework to study a network of proliferating cell populations in chronic inflammation. @DRFZ_Berlin @IEO_Bonn @ImmunoSens @HCM_Bonn
https://t.co/xhG45UjYrt
science.org
Model-based integration of kinetic in vitro and ex vivo data predicts windows of opportunity for targeted perturbation.
2
4
28
Exciting Update from EV301 trial! 🚀EV maintains survival benefit after ~2 years of follow-up. BUT: Who benefits most from EV?🎯 Our data suggest NECTIN4 as a promising predictive biomarker! @OncoAlert @urotoday @Markuseckstein3 @ViktorGruenwald
https://t.co/JmfOUNobel
#oncology
aacrjournals.org
AbstractPurpose:. The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients...
EV301 Phase III trial update (median follow-up ~2 years): Enfortumab vedotin (EV) maintained survival (HR 0.70, P = 0.00015), PFS (HR 0.63, P < 0.00001) and response rate (41.3% vs. 18.6%) benefit vs. chemotherapy in post-platinum and PD1/L1 inhibitors patients with metastatic
0
9
16